Last Updated: 10 Nov 2024
Executive Summary
Alumis Inc. (ALMS) is a pharmaceutical company with a market capitalization of $630.53 million. Despite its recent financial struggles, the company has a strong analyst rating and a favorable long-term outlook.
Company Overview
Alumis Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare diseases. The company's lead product candidate, ALM-001, is a monoclonal antibody targeting the C5a receptor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Fundamental Analysis
Alumis Inc.'s financial performance has been weak in recent quarters. The company reported a net loss of $185.06 million for the fiscal year ended December 2023, with an EPS of -$3.48. The company's revenue for the same period was $0.
Alumis Inc.'s book value per share is -$8.06, indicating that the company's liabilities exceed its assets. The company does not currently pay dividends.
Technical Analysis
The technical analysis of ALMS indicates a mixed picture. The stock's 50-day moving average is $12.31, while its 200-day moving average is $12.32. The stock is currently trading below both its moving averages.
The stock's relative strength index (RSI) is 38.5, indicating that the stock is in a neutral zone. The moving average convergence divergence (MACD) is also neutral.
Short Term Outlook
In the short term, ALMS is expected to continue to trade within a narrow range. The stock's technical indicators are neutral, and there are no major catalysts expected in the near future.
Long Term Outlook
The long-term outlook for ALMS is more favorable. The company's lead product candidate, ALM-001, has the potential to be a blockbuster drug if approved. The company also has a strong pipeline of other promising drug candidates.
Analyst Recommendations
Analysts have a strong buy rating on ALMS. The average analyst target price for the stock is $32.33, which represents a potential upside of over 160% from the current price of $12.02.
